The company maintains manufacturing arrangements with contract development and manufacturing organizations (CDMOs) and other vendors under various agreements. It holds worldwide, exclusive licenses from MD Anderson for patents related to the therapeutic use of TUSC2 and other genes, encompassing 16 issued patents and 11 pending applications. The company also holds worldwide, exclusive licenses for diabetes technologies from the University of Pittsburgh, including one issued patent and six pending applications. Additionally, it holds worldwide, exclusive licenses from the University of Michigan, New York University, and the University of Texas Health Sciences Center at Houston for patent applications concerning the use of REQORSA in certain cancers. The company is prosecuting eight patent applications related to oncology targets within its discovery program. Rights obtained from MD Anderson are subject to U.S. government rights due to funding agreements. The company pursues broad intellectual property protection through patents, trade secrets, trademarks, copyrights, and regulatory exclusivity, including data and market exclusivity under pharmaceutical laws.
Genprex Inc's Comment on Supply Chain
The company maintains manufacturing arrangements with contract development and manufacturing organizations (CDMOs) and other vendors under various agreements. It holds worldwide, exclusive licenses from MD Anderson for patents related to the therapeutic use of TUSC2 and other genes, encompassing 16 issued patents and 11 pending applications. The company also holds worldwide, exclusive licenses for diabetes technologies from the University of Pittsburgh, including one issued patent and six pending applications. Additionally, it holds worldwide, exclusive licenses from the University of Michigan, New York University, and the University of Texas Health Sciences Center at Houston for patent applications concerning the use of REQORSA in certain cancers. The company is prosecuting eight patent applications related to oncology targets within its discovery program. Rights obtained from MD Anderson are subject to U.S. government rights due to funding agreements. The company pursues broad intellectual property protection through patents, trade secrets, trademarks, copyrights, and regulatory exclusivity, including data and market exclusivity under pharmaceutical laws.
Sources:
Genprex Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Genprex Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
